patients with negative post treatment 131I-whole body scan and elevated serum thyroglobulin and patients with persistent or recurrent Hürthlecell carcinoma in the post-ablation phase and during folluw-up.
Conditions
Interventions
11C-MET PET scan.
Sponsors
no sponsor
Eligibility
Inclusion criteria
Inclusion criteria: Objective (study) 1: 1. > 18 years old; 2. Total thyroidectomy; 3. Negative post-treatment 131I-WBS with elevated Tg(on) (>5.0 ng.ml); 4. Signed informed consent. Objective (study) 2: 1. > 18 years old; 2. Total thyroidectomy; 3. Patients with persistent or recurrent Hürthlecell carcinoma in post-ablation phase or during follow-up; 4. Signed informed consent.
Exclusion criteria
Exclusion criteria: Both objectives/studies: 1. Pregnancy; 2. Patients with any signs of neurological or psychiatric disorders that will preclude him/her from expressing her/his own free will.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A qualitative and semi-quantitative (standardized uptake values (SUVs)) reading of all the PET studies will be performed. Comparison with data derived from clinical CT imaging data, and where feasible histological or cytological confirmation, will take place. Objective/Study 1: The results of 11C-MET PET will be compared with the clinical FDG PET. Objective/Study 2: The results of 11C-MET PET will be compared with the clinical FDG PET. The results of both PET scan will also be compared with the (diagnostic and) post-treatment 131I-WBS. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes. | — |
Contacts
Public ContactT.P. Links
University Medical Center Groningen Div Endocrinology PO Box 30 001
Outcome results
None listed